Table 2.

Recent phase II/III clinical trials of vaccine therapy for GBM treatment.

Vaccine type	Identifier	Title	Phase	Treatment approach	Patient type	Status
DC vaccine	NCT00045968	A phase 3 clinical trial evaluating DCVax-L, autologous dendritic cells pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme	3	DCVax-L	nGBM	Active
	NCT03548571	Open label randomized phase 2/3 trial of dendritic cell immunotherapy against cancer stem cells in glioblastoma patients receiving standard therapy (DEN-STEM)	2/3	DEN-STEM	GBM (IDH wild-type, Methylated MGMT)	Active
	NCT00639639	Anti-tumor immunotherapy targeted against cytomegalovirus in patients with newly diagnosed glioblastoma multiforme during recovery from therapeutic temozolomide-induced lymphopenia	1/2	CMV-DC	nGBM	Completed
	NCT03688178	DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab	2	DERIVe	nGBM	Active
	NCT01204684	A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen +/- Toll-like Receptor Agonists for the Treatment of Malignant Glioma	2	DC vaccine Resiquimod polyICLC	Malignant glioma	Active
	NCT02465268	A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma	2	pp65 DC vaccine	nGBM	Active
	NCT00846456	Phase I/II Trial of Vaccine Therapy With Tumor Stem Cell Derived mRNA- Transfected Dendritic Cells in Patients Receiving Standard Therapy for Glioblastoma	1/2	Tumor stem cell derived mRNA- transfected DC vaccine Stupp regimen	GBM	Completed
	NCT00323115	A Phase II Feasibility Study of Adjuvant Intra-Nodal Autologous Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme	2	DC vaccine	nGBM	Completed
	NCT01006044	Prospective, Phase II Clinical Trial to Evaluate Efficacy and Safety of Autologous Dendritic Cell Vaccination in Glioblastoma Multiforme Patients After Complete Surgical Resection With Fluorescence Microscope	2	DC vaccine	GBM	Completed
	NCT01213407	First Line Standard Therapy of Glioblastoma Multiforme With or Without add-on Treatment With Trivax, an Anti-tumour Immune Therapy Based on Tumour-lysate Charged Dendritic Cells	2	Trivax	GBM	Completed
Peptide vaccine	NCT00458601	A phase 2 study of CDX-110 with radiation and temozolomide in patients with newly diagnosed GBM	2	Rindopepimut (CDX 110) TMZ Radiotherapy	nGBM	Completed
	NCT01480479	An international randomized double, blind, controlled study of rindopepimut/GM-CSF with adjuvant temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma	3	Rindopepimut (CDX 110) TMZ	nGBM; surgically resectedGBM; EGFRvIII-positive GBM	Completed
	NCT00905060	PHASE 2, Multi-center, Single Arm Investigation of HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme	2	HSPPC-96 Temozolomide	nGBM	Completed
	NCT04280848	Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma	2	UCPVax	GBM	Active
	NCT02455557	A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma	2	SurVaxM Temozolomide	nGBM	Active
	NCT00643097	A Complementary Trial of an Immunotherapy Vaccine Against Tumor-Specific EGFRvIII	2	PEP-3-KLH conjugate vaccine	nGBM	Completed
	NCT01920191	Phase I/II Study of Intradermal IMA950 Peptide-based Vaccine Adjuvanted With Intra Muscular Poly-ICLC in Combination With Temozolomide in Newly Diagnosed HLA-A2 Glioblastoma Patients	1/2	IMA950 Poly-ICLC	GBM	Completed
	NCT00293423	Phase I/II Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Patients With Recurrent High Grade Glioma	1/2	GP96	Recurrent or progressive glioma	Completed
	NCT04116658	A Multicenter, Open-Label, First-in-Human, Phase 1b/2a Trial of EO2401, a Novel Multipeptide Therapeutic Vaccine, With and Without Check Point Inhibitor, Following Standard Treatment in Patients With Progressive Glioblastoma	1/2	EO2401	Recurrent or progressive glioma	Active
	NCT03665545	Pembrolizumab in Association With the Multipeptide Vaccine IMA950 Adjuvanted With Poly-ICLC for Relapsing Glioblastoma: a Randomized Phase I/II Trial	1/2	IMA950/Poly-ICLC Pembrolizumab	rGBM	Active

Data from ClinicalTrials.gov.